文献速递胸部肿瘤

非小细胞肺癌中SMARCA4及其他SWI/SNF家族基因组改变:临床病理特征与免疫检查点抑制剂疗效

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
PubMed 文献 · J Thorac Oncol · 2021-01-01

该研究基于Dana-Farber癌症研究所2689例NSCLC患者,发现20.6%存在SWI/SNF基因组改变,与更低可靶向驱动突变率、更高肿瘤突变负荷及更短总生存相关,其中SMARCA4突变驱动不良预后;在总体免疫治疗队列中SWI/SNF状态与疗效无关,但在KRAS突变亚组中合并SWI/SNF突变(尤其SMARCA4)与更差免疫治疗结局相关。

要点

  • NSCLC中SWI/SNF改变占20.6%,与更短OS相关,SMARCA4突变驱动该不良效应。
  • 总体免疫治疗队列中SWI/SNF状态与ORR、PFS、OS均无显著差异。
  • KRAS突变NSCLC中合并SWI/SNF突变(尤其SMARCA4)免疫治疗ORR更低、PFS和OS更短。

核心结论

  • 总体NSCLC中SWI/SNF突变状态与免疫治疗疗效无显著关联,但KRAS突变NSCLC中SMARCA4改变可能预示免疫治疗结局更差。

研究设计与样本

  • 回顾性队列研究,纳入Dana-Farber癌症研究所2689例接受靶向二代测序的NSCLC患者,基于ARID1A、ARID1B、ARID2、PBRM1、SMARCA4和SMARCB1六个SWI/SNF基因突变状态分组。

主要发现

  • SWI/SNF突变型NSCLC较野生型合并可靶向驱动突变比例更低(22.2% vs 33.2%,p<0.001),肿瘤突变负荷更高(中位12.2 vs 8.5 muts/megabase,p<0.001),晚期诊断后中位OS更短(19.3 vs 25.0月,p=0.01)。
  • SMARCA4突变型较野生型中位OS更短(15.6 vs 25.0月,p<0.001)。
  • 532例接受ICI治疗患者中25.5%携带SWI/SNF突变,野生型与突变型ORR(25.0% vs 19.9%,p=0.2)、mPFS(3.0 vs 3.0月,HR=0.96,95%CI 0.77-1.18,p=0.7)、mOS(9.5 vs 13.1月,HR=0.81,95%CI 0.64-1.02,p=0.07)均无显著差异。
  • KRAS突变NSCLC接受ICI治疗者(N=176)中,合并SWI/SNF突变(N=39)较野生型ORR数值更低(12.8% vs 21.9%,p=0.2),mPFS显著更短(1.8 vs 4.1月,HR=0.57,95%CI 0.38-0.84,p=0.005),mOS显著更短(8.2 vs 15.5月,HR=0.56,95%CI 0.36-0.86,p=0.008)。
  • KRAS突变NSCLC中SMARCA4突变亚组(N=17)较野生型ORR更低(0% vs 22%,p=0.03),mPFS显著更短(1.4 vs 4.1月,HR=0.25,95%CI 0.14-0.42,p<0.001),mOS显著更短(3.0 vs 15.1月,HR=0.29,95%CI 0.17-0.50,p<0.001)。

临床怎么用

  • 对KRAS突变NSCLC患者,检测SMARCA4及其他SWI/SNF基因改变有助于识别免疫治疗可能获益较差的人群。
  • 总体NSCLC中SWI/SNF突变状态不宜单独作为免疫治疗疗效的预判指标。

局限性

  • 研究为单中心回顾性分析,免疫治疗亚组样本量有限,尤其SMARCA4突变KRAS亚组仅17例。
  • SWI/SNF改变与免疫治疗疗效的关联需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The SWItch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling complex acts as a regulatory component of transcription, and inactivating mutations (muts) within the complex are implicated in genomic instability, higher tumor mutational burden, and an aggressive cancer phenotype. Whether SMARCA4 and other SWI/SNF alterations are independent prognostic factors or associated with clinical outcomes to immune checkpoint inhibitors (ICIs) in NSCLC remains unclear. METHODS: We collected clinicopathologic and genomic data from patients with NSCLC who underwent targeted next-generation sequencing at the Dana-Farber Cancer Institute. Tumors were characterized on the basis of the presence or absence of muts across a set of six SWI/SNF genes (ARID1A, ARID1B, ARID2, PBRM1, SMARCA4, and SMARCB1). RESULTS: Of 2689 patients with NSCLC, 20.6% (N = 555) had SWI/SNF genomic alterations. Compared with SWI/SNF wild-type (wt) NSCLC, patients with SWI/SNF-mutant NSCLCs had a lower prevalence of concurrent targetable driver muts (33.2% versus 22.2%; p < 0.001), a higher tumor mutational burden (median 8.5 versus 12.2 muts/megabase; p < 0.001), and a shorter median overall survival (mOS) from the time of advanced disease diagnosis (25.0 versus 19.3 mo, p = 0.01); the detrimental effect in OS seemed to be largely driven by SMARCA4 muts (mOS: 25.0 for SMARCA4 wt versus 15.6 mo for SMARCA4 mutant; p < 0.001). Among 532 patients who received ICIs, 25.5% (N = 136) harbored SWI/SNF muts. From the start of immunotherapy, there was no difference in objective response rate (ORR = 19.9% versus 25.0%, p = 0.2), median progression-free survival (mPFS = 3.0 versus 3.0 mo, hazard ratio [HR] = 0.96 [95% confidence interval [CI] = 0.77-1.18], p = 0.7), or mOS (13.1 versus 9.5 mo, HR = 0.81 [95% CI: 0.64-1.02], p = 0.07) in SWI/SNF-wt versus SWI/SNF-mutant NSCLC, respectively. Nevertheless, among KRAS-mutant NSCLCs treated with ICIs (N = 176), a concurrent SWI/SNF mut (N = 39) conferred a numerically lower ORR (21.9% versus 12.8%, p = 0.2), a significantly shorter mPFS (4.1 versus 1.8 mo, HR = 0.57 [95% CI: 0.38-0.84], p = 0.005), and a significantly shorter mOS (15.5 versus 8.2 mo, HR = 0.56 [95% CI: 0.36-0.86], p = 0.008). The deleterious effect on immunotherapy outcomes in KRAS-mutant NSCLC was most pronounced in the SMARCA4-mutant subset (N = 17), with a lower ORR (22% versus 0%, p = 0.03), a significantly shorter mPFS (4.1 versus 1.4 mo, HR = 0.25 [95% CI: 0.14-0.42], p < 0.001), and a significantly shorter mOS (15.1 versus 3.0 mo, HR = 0.29 [95% CI: 0.17-0.50], p < 0.001) compared with SMARCA4-wt KRAS-mutant NSCLCs. CONCLUSIONS: Although there were no associations between SWI/SNF mut status and immunotherapy efficacy in the overall NSCLC cohort, the presence of a SMARCA4 alteration may confer a worse outcome to immunotherapy among KRAS-mutant NSCLCs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Alessi JV, Ricciuti B, Spurr LF, et al. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021. PMID: 33845210. doi:10.1016/j.jtho.2021.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。